



Aastrom Biosciences to Present At BMO Capital Markets Healthcare Conference

ANN ARBOR, Mich., Jul 31, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) , a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will present at the 2008 BMO Capital Markets Focus on Healthcare Conference. The conference will be held August 5-6th at the Millennium Broadway Hotel in New York City. Aastrom will present on Tuesday, August 5, 2008 at 3:00 p.m. (Eastern Time).

A live audio webcast of Aastrom's presentation can be accessed by logging onto the web at http://audability.com/AudabilityAdmin/Clients/Aastrom/10615_85200880000AM. After the presentation, a replay will be archived for 30 days, at the same site. For more information, please visit the conference website at <http://www.bmocm.com/conferences/2008healthcare/default.aspx>.

About Aastrom Biosciences, Inc.

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries affecting cardiovascular, bone and neural tissues. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. Currently, the Company has a cardiovascular regeneration product in Phase II development for the treatment of dilated cardiomyopathy (DCM) (called the IMPACT-DCM trial) and critical limb ischemia (called the RESTORE-CLI trial), a bone regeneration product in Phase III development for the treatment of osteonecrosis of the femoral head (called the ON-CORE trial), and a preclinical research program targeting unmet needs in neural health. Aastrom product candidates to treat DCM and osteonecrosis of the femoral head have been designated for orphan drug status by the FDA. For more information, visit Aastrom's website at www.aastrom.com.

The Aastrom Biosciences, Inc. logo is available at <http://www.primenewswire.com/newsroom/prs/?pkgid=3663>

This document contains forward-looking statements, including without limitation, statements concerning clinical trial plans and expectations, clinical activity timing, intended product development and commercialization objectives, adequacy of existing capital to support operations for a specified time, future capital needs, and potential advantages and application of Tissue Repair Cell (TRC) technology, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

(astmc)

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc.

Investor Relations Department

Kris M. Maly

Kimberli O'Meara

(734) 930-5777

Cameron & Associates

Investors

Kevin McGrath

(212) 245-4577

(C) Copyright 2008 PrimeNewswire, Inc. All rights reserved.

